Skip to main content

Human pharmacokinetics of cadralazine: A new vasodilator


The pharmacokinetic profiles in plasma and the renal elimination of 2-(3-[6-(2-hydroxypropyl)ethylamino]pyridazinyl)ethylcarbazate were investigated in six healthy volunteers following single oral doses of 5, 10 and 20 mg of cadralazine. The study was run in a randomized change-over design experiment. Concentrations of cadralazine in plasma and urine were determined by a high-performance liquid chromatography method.

Maximum plasma levels (Cmax) were reached between 0.25 and 1.0 h (tmax) after administration and ranged from 69.8 to 210.0 ng/g after the 5 mg dose, 148.9 to 333.3 ng/g after the 10 mg dose and 292.9 to 474.5 ng/g after the 20 mg dose. The corresponding area under the plasma concentration-time curve (AUQ*.h) are 330, 621 and 1168 (ng/g). h. Mean renal elimination of the unchanged-drug ranged from 69 t o 73% of the dose. Mean Cmax, AUCfth and mean total renal elimination were linearly dose-related. An elimination half-life from plasma of about 2.5 h was observed for cadralazine. Estimations for the mean renal and total clearance range from 185 to 216 ml/min and 251 to 295 ml/min, respectively.

This is a preview of subscription content, access via your institution.


  1. 1.

    Semeraro C, Dorigotti L., Banfi S. and Carpi C. (1981): Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug. J. Cardiovasc. Pharmacol,3, 455–467.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Evans D.A.P. (1969): An improved and simplified method of detecting the acetylator phenotype. J. med. Genet.,6, 405–407.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Hauffe S. and Dubois J.P. (1984): Determination of cadralazine in human plasma and urine by high-performance liquid chromatography. J. Chromatogr.,290, 223–230.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Ludden T.M., McNay J.L., Shepherd A.M.M. and Lin M.S. (1982): Clinical pharmacokinetics of hydralazine. Clin. Pharmacokinet.,7, 185–202.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Van Brummelen P., Bühler F.R., Kiowski W., Bolli P. and Beitel O. (1979): Antipertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic. Int. J. Clin. Pharmacol. Biopharm.,77, 380–385.

    Google Scholar 

  6. 6.

    Simonotti L., Janol M., Parravicini F. and Pifferi G. (1982): Studies on the metabolism of cadralazine in rat. Eur. J. Drug Metab. Pharmacokinet.,7, 39–45.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Carpi C, Dorigotti L. and Semeraro C. (1981): Cadralazine and its identified metabolites: Comparative effects on blood pressure and on arterial smooth muscle. Br. J. Pharmacol.,72, 188P-189P.

    Google Scholar 

  8. 8.

    Schütz H., Faigle J.W., Küng W. and Theobald W. (1985): Disposition and pharmacokinetics of cadralazine and individual metabolites in man. Eur. J. Drug Metab. Pharmacokinet.,10, 147–153.

    PubMed  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to S. A. Hauffe.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hauffe, S.A., Dubois, J.P. & Imhof, P.R. Human pharmacokinetics of cadralazine: A new vasodilator. European Journal of Drug Metabolism and Pharmacokinetics 10, 217–223 (1985).

Download citation


  • Cadralazine
  • basic pharmacokinetics
  • healthy volunteers
  • single oral doses